Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

Shares of Novo Nordisk (NYSE: NVO) are up on Tuesday. The company's stock gained 3.9% as of 2:40 p.m. ET today and was up as much as 4.5% earlier in the day. The move up comes as the S&P 500 and ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Novo Nordisk works with Hims & Hers, Ro, LifeMD to expand Wegovy access Hims & Hers, LifeMD shares jump more than 25% and 36% respectively Danish drugmaker says move is "very clear message" Wegovy ...

Novo Nordisk announced it is partnering with telehealth platforms to offer its blockbuster drug Wegovy. The move will help it capture a large number of consumers who had flocked to digital health ...

BANGKOK, April 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's local subsidiary ...

Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard ...